Curasight CEO: “Working on accelerated plan for uTREAT”
Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development. Among other things, the much-anticipated phase II...
Prolight’s CEO: ”Proof-of-Performance in whole blood important milestone”
Prolight Diagnostics has demonstrated Proof-of-Performance in whole blood for its digital test system Psyros. It is already known that the system performs as promised...
Ultimovacs CEO: “Data could put us at the forefront of cancer...
Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO...
Scandions CMO: “Our overall survival data are quite impressive”
Scandion Oncologys läkemedelskandidat SCO-101 utvärderas för närvarande i fas II-studien CORIST för behandling av kemoterapiresistent metastaserad tjocktarmscancer. I veckan kunde bolaget meddela positiva data...
Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments”
On Tuesday morning Saniona was able to announce advancements in its Kv7-programme. The company has now concluded the lead optimisation phase and the programme...
Cline Scientific’s CEO convicted of market manipulation
Patrik Sundh, CEO and board member of Cline Scientific, has been convicted of market manipulation by the Stockholm District Court. This was announced by...
WntResearch’s CEO: “In a better position than ever”
Reporting its third quarter, WntResearch is focusing on the restart of the NeoFox study with Foxy-5. The first patient was recently enrolled in the...
Busy days for Iconovo at BIO-Europe
Iconovo had three hectic days at BIO-Europe, with a large number of meetings with potential partners. The company especially highlighted their latest innovation, ICOone...
Lipum’s SOL-116 sparked interest at BIO-Europe
On November 6-8, it was once again time for BIO-Europe, Europe's largest partnering conference in the life science sector. Lipum's CEO Einar Pontén and...
Arcede proceeds to stability study in collaboration with Iconovo
Lund-based Arcede Pharma continues to advance its project with RCD405. The company recently concluded the toxicology program and has now announced that the collaboration...
